Interleukin Genetics just got a $12 million shot in the arm, a private placement funding that will be crucial to its survival as a developer of genetic tests for chronic conditions.
According to AdvaMed, the user fees that industry players contribute to the FDA, money that currently helps the agency retain staff and support programs, may now take a hit to the tune of about $2.9 million.
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
Shire ($SHPG) is a perennial entry on everybody's favorite M&A target list. Now, according to the Daily Mail , Shire is putting its ducks in a row for a potential "special dividend" to counter any takeover interest. Word is, an £11 billion hostile bid is coming.
According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab to his government contacts--at a time when he also served on the company's board.
Global CRO Quintiles is planning to slash 400 jobs this year, the company disclosed in a regulatory filing, primarily from its product development and healthcare services departments.
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
Call it a rite of spring. Every year about this time, FiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you're a regular reader, you'll notice that this year's list is longer than previous editions. And there's a reason for that: curiosity. Check out the report >>
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
Massachusetts-based devicemaker Thermedical secured $5.5 million to hire additional staff and advance research in ablation for solid tumors and ventricular tachycardia, a dangerous arrhythmia of the heart, bringing the company's total first round of financing to $7 million.